TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05085028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 25 MG/ML [Keytruda]
Description: Pembrolizumab to be given at 400mg intravenous over 5 different frequencies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 25 MG/ML [Keytruda]
Description: Pembrolizumab to be given at 400mg intravenous over 5 different frequencies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 25 MG/ML [Keytruda]
Description: Pembrolizumab to be given at 400mg intravenous over 5 different frequencies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab 25 MG/ML [Keytruda]
Description: Pembrolizumab to be given at 400mg intravenous over 5 different frequencies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 25 MG/ML [Keytruda]
Description: Pembrolizumab to be given at 400mg intravenous over 5 different frequencies
Study: NCT05098548

Intervention type: PROCEDURE
Intervention: angioplasty
Description: using a balloon to stretch open a narrowed or blocked artery. However, most modern angioplasty procedures also involve inserting a short wire-mesh tube, called a stent, into the artery during the procedure. The stent is left in place permanently to allow blood to flow more freely .
Study: NCT06639464

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo syringes of saline and matching volume will be produced by IDS.
Study: NCT03401294

Intervention type: DRUG
Group type: OTHER
Intervention: FOLFOXIRI and Bevacizumab
Description: Every 2 week for a total of 12 cycles
Study: NCT04454515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine is an α2 receptor agonist with sedative and analgesic properties. In previous reports, dexmedetomidine improves smoothness of postoperative recovery and reduces intraoperatory imflammatory responses. As patients receiving breast surgeries are especially vulnerable to postoperative nausea/ vomiting, the dosage of narcotics and associated complications were concerned for not only comfortness but also postoperative oral intake and discharge.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: normal saline infusion
Study: NCT05697718

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC
Description: a single injection dose i.v.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC
Description: a single injection dose i.v.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC
Description: a single injection dose i.v.
Study: NCT05644873

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: magnesium sulfate group
Description: Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) \<90mmHg or \<20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR \< 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The magnesium group received a bolus of 20 mg/kg of magnesium sulfate in 100 mL of saline for 15 minutes prior to induction, followed by a continuous infusion of 20 mg/kg/hr until skin closure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: control group saline
Description: Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) \<90mmHg or \<20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR \< 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The same volume of isotonic saline for the control group was administered as indicated in the magnesium group.
Study: NCT04958863

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgical mask
Description: Use of a surgical mask during test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polyester reusable mask
Description: Use of a polyester reusable mask during test
Study: NCT05177250

Intervention type: DEVICE
Group type: OTHER
Intervention: HPLC
Description: taking urine samples from participants and analyze these samples to detect bisphenol A and paraben

Intervention type: DEVICE
Group type: OTHER
Intervention: HPLC
Description: taking urine samples from participants and analyze these samples to detect bisphenol A and paraben
Study: NCT06183398

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin prick test
Description: Specific skin prick tests for 6 raw food: peach, apple, sesame, carrot, lemon and orange
Study: NCT04575272

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided continuous serratus anterior plane block
Description: Local anesthetic infusion though a peripheral nerve catheter placed related to the serratus anterior muscle at the level of the 5th rib

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided continuous serratus anterior plane block
Description: Local anesthetic infusion though a peripheral nerve catheter placed related to the serratus anterior muscle at the level of the 5th rib
Study: NCT05443529

Intervention type: OTHER
Intervention: Adaptive sports
Description: Participation in community adaptive sports programs
Study: NCT06137365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Cannabis gummy product will be prepared using cannabis flower extract.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gummy product will be prepared using the same ingredients as the cannabis gummy but will not contain active cannabinoids.
Study: NCT04088903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: \>Daratumumab 16 mg/kg intravenous weekly for 8 weeks and then every other week for 2 doses.
Study: NCT05489328

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Candidate-1
Description: Biological

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Candidate-2
Description: Biological

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Candidate-3
Description: Biological

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Candidate-4
Description: Biological

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Candidate-5
Description: Biological

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Candidate-6
Description: Biological

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Candidate Control
Description: Biological

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 13vPnC
Description: 13-valent pneumococcal conjugate vaccine
Study: NCT05522673

Intervention type: DRUG
Group type: OTHER
Intervention: 11(R)-rolipram
Description: Injected IV followed by PET scanning
Study: NCT05489328

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PCV15
Description: 15-valent pneumococcal conjugate vaccine
Study: NCT05355727

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical decision support tool recommended outcome
Description: The PROSAIC-DS tool will take the variables and produce a suggested outcome. It will supply supporting evidence and best practice for its recommendations

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical decision support tool recommended outcome
Description: The PROSAIC-DS tool will take the variables and produce a suggested outcome. It will supply supporting evidence and best practice for its recommendations
Study: NCT06345885

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV vaccine
Description: Participants in the group A will be administrated with bivalent HPV vaccine Cecolin. The immunization schedule is 0, 6 months; Participants in the group B will be administrated with quadrivalent HPV vaccine Gardssil. The immunization schedule is 0, 2, 6 months

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HPV vaccine
Description: Participants in the group A will be administrated with bivalent HPV vaccine Cecolin. The immunization schedule is 0, 6 months; Participants in the group B will be administrated with quadrivalent HPV vaccine Gardssil. The immunization schedule is 0, 2, 6 months
Study: NCT05767281

Intervention type: BEHAVIORAL
Intervention: prevention program
Description: introduction of the developed comprehensive prevention program among the child population with the participation of primary health care personnel, which will improve not only the dental health of children, their quality of life, but will also help reduce foci of chronic oral sepsis.

Intervention type: BEHAVIORAL
Intervention: prevention program
Description: introduction of the developed comprehensive prevention program among the child population with the participation of primary health care personnel, which will improve not only the dental health of children, their quality of life, but will also help reduce foci of chronic oral sepsis.

Intervention type: BEHAVIORAL
Intervention: prevention program
Description: introduction of the developed comprehensive prevention program among the child population with the participation of primary health care personnel, which will improve not only the dental health of children, their quality of life, but will also help reduce foci of chronic oral sepsis.
Study: NCT05674838

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leg Elevation
Description: Immediately after epidural placement, patient will be placed in a left tilt position with her hip on a wedge and both of her legs elevated on an orange peanut ball. She will remain in this position for approximately 40 minutes.
Study: NCT04579679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: Surufatinib 300 mg oral once daily
Study: NCT06555211

Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI
Description: MRI will be performed

Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI
Description: MRI will be performed

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PET/CT
Description: PET/CT will be performed

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PET/CT
Description: PET/CT will be performed
Study: NCT05172193

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-COV-2 Vaccine (Vero Cell-Sinopharm) Inactivated
Description: SARS-CoV-2 vaccine (Vero cell) inactivated developed by Beijing Bio-Institute Biological Products Co., Ltd, can induce active immunity and prevent diseases caused by the SARS-CoV-2 virus by producing neutralizing antibody. The inactivated SARSCoV-2 Vaccine (Vero cell) is prepared by inoculating Verda Reno cells (Vero cell) with SARS-CoV-2 HB02 strain, culturing, harvesting, inactivating, clarifying, concentrating, purifying and adding aluminum hydroxide adjuvant.
Study: NCT05597280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BE-PEP Bedaquiline
Description: bedaquiline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SDR-PEP Rifampicin
Description: SDR-PEP: rifampicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BE-PEP Rifampicin
Description: BE-PEP rifampicin
Study: NCT05517161

Intervention type: BEHAVIORAL
Intervention: INSIGHT
Description: See Keegan et al., 2020
Study: NCT05557448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TYNADOTE
Description: Subjects will take 200 mg/every 4 hours, with a loading dose (400 mg) and then followed by 17 maintenance doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Subjects will take 200 mg/every 4 hours, with a loading dose (400 mg) and then followed by 17 maintenance doses
Study: NCT06346873

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JOGO
Description: AI driven mobile app and wearable sensors to provide virtual treatments
Study: NCT06094907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N,N-Dimethyltryptamine
Description: DMT will be administered using a vaporizer device in an ascending fixed-order of 15mg and 60mg.
Study: NCT05830513

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality
Description: Women will be randomly allocated to undergo OPU either with the use of virutal reality (group A) or the control group with standard treatment, without analgesia(group B). The participants of group A will wear the Oculus Quest 2 and will be surrounded by a virtual world. They will see objects flying towards themselves. They will be able to interact with the virtual world by hand controllers and can try to catch the objects.
Study: NCT04781881

Intervention type: DRUG
Intervention: Entresto
Description: There is no treatment allocation. Patients administered Entresto by prescription that have started before inclusion of the patient into the study will be enrolled.
Study: NCT05701397

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: DPD scintigraphy
Description: Bone tracer scintigraphy, diagnostic for transthyretin cardiac amyloidsis
Study: NCT04960072

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes (TIL)
Description: Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
Study: NCT05268315

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Psychoeducational Intervention
Description: The 1-session psychoeducational intervention is divided into three brief modules. Topics that are covered include thinking, learning, emotional, and behavioral functioning as they relate to childhood cancer, educational and school supports, and the role of neuropsychological and school-based assessments.
Study: NCT06250517

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EVLP
Description: The right lung will be perfused for 3h with EVLP
Study: NCT05767281

Intervention type: BEHAVIORAL
Intervention: prevention program
Description: introduction of the developed comprehensive prevention program among the child population with the participation of primary health care personnel, which will improve not only the dental health of children, their quality of life, but will also help reduce foci of chronic oral sepsis.

Intervention type: BEHAVIORAL
Intervention: prevention program
Description: introduction of the developed comprehensive prevention program among the child population with the participation of primary health care personnel, which will improve not only the dental health of children, their quality of life, but will also help reduce foci of chronic oral sepsis.
Study: NCT06250517

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cold preservation
Description: The left lung will be cold preserved as usual protocol
Study: NCT04994444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicoderm CQ 21Mg/24Hr Transdermal System
Description: Nicoderm CQ patch started 3 weeks prior to quit date. Starting on quit date, patch/gum or patch/lozenge will be used for 8 weeks. Patch will be tapered over the 8 week period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicoderm CQ 21Mg/24Hr Transdermal System
Description: Nicoderm CQ patch started 3 weeks prior to quit date. Starting on quit date, patch/gum or patch/lozenge will be used for 8 weeks. Patch will be tapered over the 8 week period.
Study: NCT05767281

Intervention type: BEHAVIORAL
Intervention: prevention program
Description: introduction of the developed comprehensive prevention program among the child population with the participation of primary health care personnel, which will improve not only the dental health of children, their quality of life, but will also help reduce foci of chronic oral sepsis.
Study: NCT06107478

Intervention type: OTHER
Intervention: Self-report questionnaires (only for parents)
Description: Quantitative part (all investigating centers): When they come to the various timepoints (T0, T1, T2), participants will be asked to fill in self-questionnaires, either electronically or on paper. If they are unable to come to the center at T1 and/or T2, they will be offered the option of completing the self-questionnaires online. These can also be sent by e-mail or postal mail and received by the same means if necessary.~The tools:~* Quality of life: Pediatric Quality of Life Inventory~* Anxiety: Edmonton Symptom Assessment System; Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety Scale~* Depression: Edmonton Symptom Assessment System; PROMIS depression scale~* Parent-child relationship: Ad hoc questionnaire~* Parent-caregiver relationship: Enabling Practices Scale Socio-demographic data on parents and children, data relating to supportive care will be collected at inclusion. Massage habits will be collected at T1 and T2.

Intervention type: OTHER
Intervention: Interview (only for parents)
Description: Qualitative part (exclusively at CLB):~Participants (parents) in the qualitative part of the study will be asked to complete a self-administered questionnaire on socio-demographic data when they come to the center at T0. Clinical data will also be collected at T0. At T1, an interview will be organized with a researcher dedicated to the study. Qualitative interviews will preferably take place face-to-face, although videoconferencing may be used in certain circumstances.
Study: NCT05668312

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-prehabilitation
Description: Preoperative tele-rehabilitation using a virtual reality system.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard prehabilitation
Description: Preoperative home-based rehabilitation delivered with a printed booklet for the Con-O subjects and no intervention for the Con-Y subjects.
Study: NCT06107478

Intervention type: OTHER
Intervention: Clinical data collection (only concerning Children)
Description: The children's medical data (patients) will be collected in a Case Report Form (CRF; e.g. type of cancer, date of diagnosis, anti-cancer treatments received, symptoms) at T0.
Study: NCT05616078

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laser treatment
Description: a maximum of 4 sessions, with an interval of 3 to 4 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy
Description: a maximum of 4 sessions, with an interval of 3 to 4 weeks
Study: NCT05807386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based exercise programme
Description: A 12 week, online delivered, home-based exercise programme.
Study: NCT05714007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric derisomaltose
Description: Single intravenous dose ferric derisomaltose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous succinate
Description: Daily oral dose of 100 mg iron (ferrous succinate) tid postoperatively
Study: NCT05466032

Intervention type: OTHER
Intervention: Osteopathic Manual Manipulation (OMM) Curriculum
Description: Osteopathic medical students are enrolled in the OMM curriculum while masters students are not enrolled.
Study: NCT06146647

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive body image TV show
Description: This is a 15 minute (approximately) show that has positive body image content embedded in the storyline. It also showcases a diverse range of body sizes in the casting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive body image music video
Description: This is a positive body image song with strong visual representation of diverse body sizes in the music video.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control TV show about a visit to the dentist
Description: 14 minute tv show following a tv character as he visits the dentist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control music video about brushing teeth
Description: Music video of a tv character singing about brushing teeth
Study: NCT05751759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitiperstat
Description: Participants receive mitiperstat orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitiperstat
Description: Participants receive mitiperstat orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitiperstat
Description: Participants receive mitiperstat orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitiperstat
Description: Participants receive mitiperstat orally.
Study: NCT05237440

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Biological dosage
Description: Metabolic, hormonal and psychometric evaluations will be carried out during inclusion inflammatory parameters, hormonal, capillary, saliva and urine assays will also be carried out at inclusion
Study: NCT05319834

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin tablet
Description: group1: oral aspirin at a dose of 100mg once daily at the same time with progesterone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: group 2: oral placebo once daily at the same time with progesterone
Study: NCT05310799

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared Decision Making (SDM)
Description: The intervention is a structured SDM discussion between physician and family, occurring at the time of the child's JIA diagnosis and clinic visit. Discussion will be guided by a discussion guide and the PERSON-JIA Report, which is generated in real time on the physician's smart phone.
Study: NCT05916521

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.454% stannous fluoride
Description: Brush two times daily

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 0.76% sodium monofluorophosphate
Description: Brush two times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride AM and 0.76% sodium monofluorophosphate PM
Description: Brush two times daily
Study: NCT05975749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: Serplulimab: 4.5mg/Kg on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzuma
Description: Trastuzuma: 8mg/Kg ( the first cycle)，6mg/Kg (the rest of cycles) on day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapy: Capecitabine or S-1 and Oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² or S-1 40 mg/m2 twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy: Capecitabine or S-1 and Oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² or S-1 40 mg/m2 twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease